Literature DB >> 16096289

The failure of antibiotics to prevent heart attacks.

David Taylor-Robinson, Jens Boman.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16096289      PMCID： PMC1184236          DOI： 10.1136/bmj.331.7513.361

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  13 in total

Review 1.  Chlamydia pneumoniae in arteries: the facts, their interpretation, and future studies.

Authors:  D Taylor-Robinson; B J Thomas
Journal:  J Clin Pathol       Date:  1998-11       Impact factor: 3.411

2.  Progression of early carotid atherosclerosis is only temporarily reduced after antibiotic treatment of Chlamydia pneumoniae seropositivity.

Authors:  Dirk Sander; Kerstin Winbeck; Jürgen Klingelhöfer; Thorleif Etgen; Bastian Conrad
Journal:  Circulation       Date:  2004-02-09       Impact factor: 29.690

3.  Antibiotics in the prevention of heart attacks.

Authors:  John Danesh
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

4.  Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome.

Authors:  Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; J Thomas Grayston; Brent Muhlestein; Robert P Giugliano; Richard Cairns; Allan M Skene
Journal:  N Engl J Med       Date:  2005-04-21       Impact factor: 91.245

5.  High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors.

Authors:  J Boman; S Söderberg; J Forsberg; L S Birgander; A Allard; K Persson; E Jidell; U Kumlin; P Juto; A Waldenström; G Wadell
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

6.  Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment.

Authors:  J Gieffers; H Füllgraf; J Jahn; M Klinger; K Dalhoff; H A Katus; W Solbach; M Maass
Journal:  Circulation       Date:  2001-01-23       Impact factor: 29.690

7.  Antibiotics for the secondary prevention of ischemic heart disease: a meta-analysis of randomized controlled trials.

Authors:  Brian J Wells; Arch G Mainous; Lori M Dickerson
Journal:  Arch Intern Med       Date:  2004-10-25

8.  Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction.

Authors:  S Gupta; E W Leatham; D Carrington; M A Mendall; J C Kaski; A J Camm
Journal:  Circulation       Date:  1997-07-15       Impact factor: 29.690

9.  Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study.

Authors:  B Timothy Baxter; William H Pearce; Eugene A Waltke; Fred N Littooy; John W Hallett; K Craig Kent; Gilbert R Upchurch; Elliot L Chaikof; Joseph L Mills; Beverly Fleckten; G Matt Longo; Jason K Lee; Robert W Thompson
Journal:  J Vasc Surg       Date:  2002-07       Impact factor: 4.268

10.  Association of circulating Chlamydia pneumoniae DNA with cardiovascular disease: a systematic review.

Authors:  Marek Smieja; James Mahony; Astrid Petrich; Jens Boman; Max Chernesky
Journal:  BMC Infect Dis       Date:  2002-10-01       Impact factor: 3.090
View more
  3 in total

Review 1.  Infection and Atherosclerosis Development.

Authors:  Lee Ann Campbell; Michael E Rosenfeld
Journal:  Arch Med Res       Date:  2015-05-21       Impact factor: 2.235

2.  Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial.

Authors:  Christian M Jespersen; Bodil Als-Nielsen; Morten Damgaard; Jørgen Fischer Hansen; Stig Hansen; Olav H Helø; Per Hildebrandt; Jørgen Hilden; Gorm B Jensen; Jens Kastrup; Hans Jørn Kolmos; Erik Kjøller; Inga Lind; Henrik Nielsen; Lars Petersen; Christian Gluud
Journal:  BMJ       Date:  2005-12-08

Review 3.  Persistent C. pneumoniae infection in atherosclerotic lesions: rethinking the clinical trials.

Authors:  Lee Ann Campbell; Michael E Rosenfeld
Journal:  Front Cell Infect Microbiol       Date:  2014-03-21       Impact factor: 5.293
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.